NHS England has urged women to accept cervical screening invites to make it possible to eliminate the disease within the next two decades.
Screening using a highly effective test helps detect human papillomavirus (HPV), which is responsible for over 99 per cent of all cervical cancers.
Sadly, three in ten of those eligible for screening do not take up the potentially life-saving offer, as shown by the NHS Cervical Screening Programme,
England 2022-2023 annual report.
The report, published by NHSE on Thursday, showed that a total of 4.62 million women aged 25 to 64 for cervical screening was invited to book an appointment
in 2022-23, and 3.43 million attended the screening.
Regular health screenings are an essential part of maintaining wellness, and one vital test for women is the Pap smear. Known for its role in early
detection of cervical cancer, the Pap smear is a simple yet powerful tool that can potentially save lives. In this blog, we will explore the significance of Pap
smears, what the procedure involves, and how often you should get tested.
The Importance of Regular Local Screenings
Staying on top of your health requires vigilance, and regular local screenings play an indispensable role in this effort. Local screenings, like Pap smears, are
essential in detecting potential health issues at their earliest stages, making treatments more effective and improving outcomes.
By participating in these routine checks, you not only safeguard your health but also contribute to broader public health efforts by identifying and addressing
potential outbreaks or health trends within the community. Whether that's HPV and Pap tests in Singapore or a mammogram in the US, local screenings are crucial
for maintaining overall wellness. This is especially true for Pap smears, as they play a significant role in detecting and preventing cervical cancer.
Morning friends,today i would like to stress on the importance of screening programmes for early detection of cervical cancer.Cervical cancer is perhaps the most common female genital tract cancer in the developing countries
MD Anderson Cancer Center and Ascentage Pharma entered into a five-year collaboration that aims to accelerate clinical development of novel apoptosis-targeted and tyrosine kinase inhibitor drug candidates for leukemia treatment.
Read the complete report Click on http://bit.ly/2NIzta5